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osting by EAbstract Pulmonary embolism (PE) remains a major cause of morbidity and mortality in the gen-
eral population, the established treatment for PE is anticoagulation. It has previously been demon-
strated that thrombolytic therapy can be lifesaving in patients with massive PE (haemodynamic
instability and right heart failure). However, the use of thrombolytic therapy in patients with sub-
massive PE (haemodynamically stable) remains a controversial topic. Recent clinical studies, how-
ever, support evidence that thrombolysis may favorably affect the outcomes in a wider spectrum of
high risk PE patients presenting with right ventricular dysfunction (RVD) as evidenced by
decreased right ventricular end diastolic diameter (RVEDD), disappearance of paradoxical septal
motion (PSM), and tricuspid regurge (TR) as well as decrease in the pulmonary artery pressure.
The aim of this study was to evaluate the efﬁcacy and safety of high dose streptokinase (SK) in
1 h versus low dose SK in 24 h in patients with submassive PE and RVD (high risk PE). The study
included 60 patients (28 males and 32 females, mean age 45.5 ± 13.6 years) with submassive PE
(positive spiral CT chest) and RVD (proved by echocardiography). Those without contraindica-
tions to SK were randomly assigned to receive either high dose (group I) or low dose (group II)
of SK. Those with contraindication(s) to SK received anticoagulation (group III). Echocardiogra-
phy was done before and 72 h after treatment. Right ventricular dysfunction (RVEDD, PSM, and
TR) and mean pulmonary artery pressure (PAP) improved signiﬁcantly 72 h after treatment inhoo.com (A.A. Abdelsamad).
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68 A.A. Abdelsamad et al.groups I and II, while a slight improvement in PAP was observed after treatment in group III. No
signiﬁcant difference was noticed between groups I and II regarding the effect of treatment on RVD
or PAP. Statistically nonsigniﬁcant difference was found between groups I and II regarding the
complications of SK, however a slightly higher risk of bleeding was observed in group I (high dose
SK). No signiﬁcant difference was found between the three groups regarding the mortality. These
data suggest that SK can rapidly and safely reverse the pulmonary hypertension and RVD in con-
trast to anticoagulation. Both protocols of SK are equieffective in rapid reversal of RVD and pul-
monary hypertension. Both protocols were safe as proved by absence of difference in mortality over
anticoagulant group.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pulmonary embolism (PE) is a common disorder associated
with substantial morbidity and mortality; autopsy series have
shown that PE is responsible for 15% of all in-hospital
deaths.1
Anticoagulants remain the standard of care for venous
thromboembolism (VTE); anticoagulation prevents clot prop-
agation and allows endogenous ﬁbrinolytic activity to dissolve
existing thrombi, a process that typically occurs over several
weeks or months. Thrombolytic therapy, by actively dissolving
thromboembolic, offers several potential advantages over anti-
coagulation in the treatment of patients with VTE.2
Thrombolysis is an established treatment for patients with
massive PE and haemodynamic instability (cardiogenic shock
or persistent arterial hypotension). In contrast, the effect of
thrombolytic agents on the outcome of haemodynamically sta-
ble patients who have submassive PE has been debated for
decades.3,21,22
Registry data indicate that right ventricular dysfunction
(RVD) in patients with PE is associated with an increased risk
of fatal outcomes even in patients who are haemodynamically
stable.4,18,19
The indication and rationale for thrombolysis in submas-
sive PE remain debatable as no large-scale randomized con-
trolled clinical trials comparing thrombolytic agents, or
thrombolysis and anticoagulation to anticoagulation alone
have been performed.5,18,19,21
The aim of this study was to compare the efﬁcacy and
safety of high dose streptokinase (SK) in 1 h versus low dose
SK in 24 h in patients with submassive PE and RVD.
2. Patients and methods
Sixty patients (28 males and 32 females) with submassive PE
and RVD were enrolled in the study. The mean age was
45.5 ± 13.6 years (range 22–75 years).
2.1 Inclusion criteria
(a) Proven PE by spiral CT scan of the chest. (b) Evidence of
pulmonary hypertension and/or RVD (RV dysfunction)
including increased right ventricular end diastolic diameter
(RVEDD), paradoxical inter-ventricular septal motion
(PSM), and tricuspid regurge (TR). (c) Patients age range
18–75 years. (d) Patients referred within 14 days after the onset
of symptoms.2.2. Exclusion criteria
(a) Normal echocardiographic examination (minor PE). (b)
Haemodynamic instability or cardiogenic shock (massive
PE). (c) Previous PE.
2.3. Protocol
Patients without contraindications to thrombolysis were ran-
domly assigned to receive either high dose SK; 1,500,000 U
over 1 h (group I; included 15 patients) or low dose SK;
250,000 U over 30 min followed by100,000 U/h for 24 h (group
II; included 25 patients). Thrombolysis was followed by anti-
coagulant therapy (unfractionated heparin and warfarin).
Those with contraindication(s) to thrombolysis received anti-
coagulant therapy (group III; included 20 patients).
2.4. Contraindications for thrombolysis (risk of bleeding)
Cerebrovascular accident, intracranial trauma or surgery
within the last 2 months; active intracranial disease (neo-
plasm, aneurysm, vascular malformation); major internal
bleeding within past 6 months; uncontrolled hypertension
(systolic blood pressure >200 mmHg, diastolic blood pres-
sure >110 mmHg); bleeding diathesis, coagulopathies or
platelet count <100,000 mm3; recent major surgery, organ
biopsy or labour (within 10 days); recent trauma; infective
endocarditis/pericarditis; pregnancy; aortic aneurysm; hemor-
rhagic retinopathy; decompensated liver disease, and renal
failure.7
2.5. Pre-treatment evaluation
This included recording of the vital signs, arterial blood gases,
ECG, chest X-ray (CXR), study of the venous system of the
lower limbs using Duplex ultrasound, post-contrast spiral
CT of the chest, echocardiography (for measurement of PAP
and evidence of RVD: RVEDD, PSM, and TR), and labora-
tory tests (CBC, INR, PTT, and creatinine).
2.6. Post-treatment evaluation
Seventy-two hours after treatment the following data were
reevaluated: vital signs, arterial blood gases, and echocardiog-
raphy (for re-measurement of PAP and detection of RVD:
RVEDD, PSM, and TR).
Table 2 Changes of arterial blood gases parameters (as a
percentage of pre-treatment values) in groups I, II, and III.
Group I Group II Group III P value
PaO2 19 ± 9.5 25 ± 14.8 20 ± 20.4 0.606
PaCO2 7.7 ± 6.2 9 ± 13.3 13.3 ± 15.6 0.494
P(A-a)O2 33.7 ± 8.7 37.2 ± 9.3 35.6 ± 15.5 0.802
Table 3 Changes in RVEDD, PAP, PSM, and TR after
treatment in group I.
Pre-treatment Post-treatment P value
RVEDD (cm) 3.4 ± 0.3 2.7 ± 0.2 0.000
PAP(mmHg) 50.9 ± 7.7 39.0 ± 6.6 0.000
PSM
Present (%) 63.6 0 0.005
Absent (%) 36.4 100
TR grade
0 (%) 0 25 0.005
1 (%) 18.2 62.5
2 (%) 54.5 12.5
3 (%) 27.3 0
Table 4 Changes in RVEDD, PAP, PSM, and TR after
treatment in group II.
Pre-treatment Post-treatment P value
RVEDD (cm) 3.1 ± 0.3 2.5 ± 0.2 0.000
PAP (mmHg) 53.1 ± 4.8 42.6 ± 5.8 0.000
PSM
Present (%) 47.4 0 0.000
Absent (%) 52.6 100
TR grade
0 (%) 21.1 41.2 0.000
1 (%) 15.8 58.8
2 (%) 63.2 0
3 0 0
Table 5 Changes in RVEDD, PAP, PSM, and TR after
treatment in group III.
Pre-treatment Post-treatment P value
RVEDD (cm) 3.0 ± 0.4 3.0 ± 0.4 1.0
PAP (mmHg) 47.0 ± 9.4 44.4 ± 6.8 0.05
PSM
Present (%) 50 50 0.317
Absent (%) 50 50
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Data were analyzed using SPSS program version 10. Qualita-
tive data were presented as a percent and comparison between
groups was done by v2-test. Quantitative data were tested for
normality by Kolmogrov–Smirnov test. Normally distributed
data were presented as mean ± SD. Paired t-test was used
for comparison within groups and unpaired t-test was used
to compare between two groups. One Way ANOVA was used
to compare between more than two groups. A P-value <0.05
was regarded as signiﬁcant.
3. Results
3.1. Respiratory rate and heart rate changes
There was signiﬁcant decrease in the heart rate and respiratory
rate after treatment in the three groups. No signiﬁcant differ-
ence regarding the post-treatment changes of heart rate and
respiratory rate among the three groups was found (Table 1).
3.2. Arterial blood gases changes
The PaO2 and PaCO2 increased signiﬁcantly after treatment in
the three groups. The alveolar-arterial oxygen gradient
[P(A-a)O2] decreased signiﬁcantly in the three groups. There
was no signiﬁcant difference regarding post-treatment changes
in PaO2, PaCO2, and P(A-a)O2 among the three groups
(Table 2).
3.3. Echocardiographic changes
Right ventricular dysfunction (RVEDD, PSM, and TR) and
mean pulmonary artery pressure (PAP) improved signiﬁcantly
72 h after treatment in groups I and II, while a statistically
nonsigniﬁcant improvement in PAP was observed after treat-
ment in group III, with no any improvement in the RVD
(RVEDD, PSM, and TR) in that group (Tables 3–5).
There was a signiﬁcant difference regarding post-treatment
changes in RVEDD and PAP among the three groups
(Table 6); highly signiﬁcant difference was found between
groups I + II versus group III (Table 7) while no signiﬁcant
difference could be seen between groups I and II (Table 8).
The post-treatment changes in PSM and TR were not
signiﬁcantly different between groups I and II (Table 9).
3.4. Complications of SK therapy
Complications following treatment with SK in 40 patients
(groups I and II) were as follow: transient low grade fever in
four patients (10%), transient hypotension in three patients
(7.5%), major bleeding (GIT) in one patient (2.5%), andTable 1 Changes of heart rate (HR) and respiratory rate (RR)
(as a percentage of the pre-treatment values) in groups I, II, and
III.
Group I Group II Group III P value
HR 18.2 ± 8.4 24.9 ± 6.1 21.8 ± 8.7 0.136
RR 22.0 ± 7.7 24.8 ± 6.4 22.7 ± 4.6 0.431
TR grade
0 (%) 60 57.9 1.0
1 (%) 25 26.3
2 (%) 15 15.8
3 0 0allergy in one patient (2.5%) (Table 10). No signiﬁcant differ-
ence was found between groups I and II regarding the compli-
cations of SK (Table 11).
Table 6 Changes of right ventricular end diastolic diameter
(RVEDD) and mean pulmonary artery pressure (PAP) (as a
percentage of pre-treatment values) in groups I, II, and III.
Group I Group II Group III P value
RVEDD 19.5 ± 4.2 20.5 ± 6.8 0.000 0.000
PAP 23.4 ± 4.8 19.9 ± 5.7 4.9 ± 6.4 0.000
Table 7 Changes of right ventricular diameter (RVEDD) and
mean pulmonary artery pressure (PAP) (as a percentage of pre-
treatment value) in groups (I + II) versus group III.
Group I + II Group III P value
RVEDD 20.1 ± 6 0.00 0.000
PAP 21.1 ± 5.6 4.9 ± 6.4 0.000
Table 8 Changes of right ventricular diameter (RVEED) and
mean pulmonary artery pressure (PAP) (as a percentage of pre-
treatment value) in groups I and II.
Group I Group II P value
RVEDD 19.5 ± 4.2 20.5 ± 6.8 1.0
PAP 23.4 ± 4.8 19.9 ± 5.7 0.536
Table 9 Changes in paradoxical septal wall motion (PSM)
and tricuspid regurge (TR) after treatment in groups I and II.
Group I (%) Group II (%) P value
PSM
Present 0 0 1.0
Absent 100 100
TR grade
0 25 41.2 0.3
1 62.5 58.8
2 12.5 0
3 0 0
Table 10 Complications of SK therapy in groups I and II (30
cases).
No %
Fever 4 10
Hypotension 3 7.5
Major bleeding (GIT) 1 2.5
Allergy 1 2.5
Table 11 Comparison of complications of SK therapy
between groups I and II.
Group I (%) Group II (%) P value
Fever 18.2 10.5 0.6
Hypotension 9.1 10.5 0.9
Major bleeding (GIT) 9.1 0 0.2
Allergy 0 5.3 0.4
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There was no mortality in group I, one death in group II (4%),
and one death in group III (5%). No signiﬁcant difference was
found between the three groups regarding the mortality.4. Discussion
This study was planned to evaluate the efﬁcacy and safety of
thrombolytic (streptokinase) therapy in patients with submas-
sive PE and right ventricular dysfunction. The recovery of
right ventricular function was considered as a marker of
thrombolysis efﬁcacy.8,20
The study included 60 patients with high risk submassive
PE (with RVD) as proved by spiral CT and RVD on echocar-
diogram. Three therapeutic protocols were used, those with
RVD and without a contraindication for thrombolysis were
randomized to receive either a high dose, short term streptoki-
nase (SK) (1,500,000 IU over 1 h) or low dose, long term strep-
tokinase (250,000 IU over 30 min then 100,000 IU every hour
for 24 h). Those with RVD and with a contraindication for
thrombolytic treatment received anticoagulant therapy alone.
4.1. High dose SK (group I)
The efﬁcacy of treatment was proved by rapid recovery of the
right ventricular function on echocardiogram. RVEDD
decreased signiﬁcantly from 3.4 ± 0.3 to 2.7 ± 0.2 cm, PAP
decreased by 23.4%, PSM and TR severity improved in all pa-
tients. These data suggest a rapid reversal of pulmonary hyper-
tension and right ventricular dysfunction after thrombolysis.
The efﬁcacy of high dose SK in treatment of PE with RVD
was conﬁrmed in previous studies. Jerjes-Sanchez et al.9 stud-
ied the effect of high-dose and short term SK protocol
(1,500,000 IU over 1 h) in patients with massive PE. Patients
randomly received either SK or heparin therapy. All patients
who received heparin alone died, whereas no deaths occurred
in the SK group. Also in another study Jerjes-Sanchez et al.6
used high dose and short term SK in 40 patients with massive
PE and RVD, 40% of patients were shocked. Survivors
showed improved haemodynamic and echocardiogram param-
eters as early as 24 h post-treatment.
Meneveau et al.10 studied the effect of high dose SK in 43
patients with massive PE showing a rapid reversal of pulmon-
ary hypertension and RVD.
4.2. Low dose SK (group II)
As with the high dose SK protocol; the efﬁcacy of treatment
was proved by rapid recovery of the right ventricular function
on echocardiogram. The RVEDD signiﬁcantly decreased from
3.1 ± 0.3 to 2.5 ± 0.2 cm, PAP decreased by 19.9%, TR
severity and PSM improved in all patients. Again, the results
suggest that low dose long term SK is also effective in reversing
the pulmonary hypertension and RVD.
The efﬁcacy of low dose SK in PE was tested in previous
studies; The Urokinase-Streptokinase Embolism Trial11,20 stud-
ied the effect of low dose SK (250,000 U over 30 min then
100,000 IU/h for 24 h). There was improvement in angio-
graphic severity scores and haemodynamic variables 24 h
post-treatment. Ly et al.12 studied the effect of (250,000 IU
Efﬁcacy and safety of high dose versus low dose streptokinase for treatment 71SK bolus then 100,000 IU/h for 72 h) in 14 patients with mas-
sive PE. The degree of angiographic improvement was signiﬁ-
cantly greater in the SK group compared to the heparin group.
Meneveau et al.13 studied the effect of SK (250,000 U bolus
then 100,000 IU every hour for 12 h) in 25 patients with mas-
sive PE. A rapid improvement in pulmonary artery pressure
and pulmonary vascular resistance were observed.
4.3. High dose versus low dose SK
In the present study, the two protocols using SK (high dose and
lowdose)were equieffective and safe as provedby absence of sig-
niﬁcant difference between the degrees of improvement in the
RVD however the low dose SK was associated with less risk of
major bleeding (Table 11), this ﬁnding is similar to that found
by Wang et al.20, major (GIT) bleeding had occured in one pa-
tient in group I, which represent 2.5% of the total SK patients.
4.4. Thrombolysis versus anticoagulation (group III)
Twenty patients with submassive PE and RVD received
heparin only due to presence of contraindication to SK. The
response was measured 72 h post-treatment showing signiﬁ-
cant changes in HR, RR, and ABGs parameters. But a statis-
tically nonsigniﬁcant decrease in PAP and no improvement in
RVD (RVEDD, PSM, and TR) were observed. Although there
were no signiﬁcant difference between the SK and the heparin
treatment regarding the post-treatment changes in HR, RR,
blood and ABGs parameters, only patients who received SK
showed a signiﬁcant improvement in RVD. Also the decrease
in PAP was signiﬁcantly larger after the SK treatment com-
pared to the heparin treatment. These data suggested that only
SK can rapidly reverse the pulmonary hypertension and RVD.
These results support the ﬁndings of previous studies com-
paring heparin and streptokinase in PE. Ly et al.12 compared
heparin with SK treatments; the greater improvement was
evaluated angiographically in SK group. Hamel et al.14 com-
pared 64 patients treated with thrombolysis with 64 patients
treated with heparin only (submassive PE); the improvement
in lung perfusion was 42% and 65% in the heparin and the
SK groups, respectively. Goldhaber et al.15 reported that in
patients with submassive PE treated with heparin the RV func-
tion improved by 17% only.
4.5. Complications of thrombolysis
Apart from major bleeding (GIT) in one patient (2.5%) who
received high dose SK, other complications were minor. Minor
complication included low grade fever (10%), transient hypo-
tension (7.5%) and allergy (2.5%). These results are compara-
ble to the results reported by others; Jerjes-Sanchez et al.6;
reported 1 case (2.5%) with major hemorrhage and 4 cases
(10%) with minor complications such as transient hypoten-
sion, skin allergy and rigors. Meneveau et al.10; reported 3
cases (7%) with major hemorrhage in patients who received
high dose SK.
In this study there was no mortality in group I (high dose
SK) this was similar to the ﬁnding of Meneveau et al.10 who
reported no mortality with high dose, while Jerjes-Sanchez
et al.6 reported 12.5% mortality in patients receiving high dose
SK. One death (4%) was observed in group II (low dose SK).
Similar ﬁgures were reported in previous studies using a similarprotocol. Ly et al.12 reported 7.1% mortality while Meneveau
et al.13 reported 4% mortality. The mortality rate in heparin
group was (5%) similar to those previously reported by others
using heparin treatment; Thabut et al.16 reported 5.8% mortal-
ity and Goldhaber et al.15 reported 3.6%. In the present study
no signiﬁcant difference in mortality was found between the
three groups. This is in agreement with Agnelli et al.17 and
Thabut et al.16 who concluded that thrombolytic therapy con-
ferred no mortality disadvantage over heparin. This is in con-
trast to Jerjes-Sanchez et al.9 where all patients who received
heparin died while those who received SK survived and this
was the only study which demonstrated survival advantage
in thrombolytic therapy over heparin therapy.
In conclusion; in contrast to heparin; the SK treatment rap-
idly and safely reverse the RVD and pulmonary hypertension
in patients with submassive PE. The low dose SK was as effec-
tive as the high dose SK treatments with less risk of bleeding.
The SK treatment was as safe as heparin as regards complica-
tions and mortality.References
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